Get the Stockscreener App
106.74
2.10%
-2.29
After Hours:
106.74
Glaukos Corporation stock is traded at $106.74, with a volume of 498.15K.
It is down -2.10% in the last 24 hours and down -3.76% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$109.03
Open:
$108.87
24h Volume:
498.15K
Relative Volume:
0.59
Market Cap:
$6.13B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-36.06
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-5.97%
1M Performance:
-3.76%
6M Performance:
+19.48%
1Y Performance:
-25.69%
1-Day Range:
$105.37
$109.34
1-Week Range:
$105.37
$115.19
52-Week Range:
$73.16
$161.78
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
106.74 | 6.26B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Globus Medical (GMED) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
Stifel reiterates Buy rating on Glaukos stock with $160 price target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Glaukos stock with $160 price target - Investing.com Australia
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
What is Glaukos Corporation’s market position2025 Major Catalysts & Weekly Momentum Picks - mfd.ru
Glaukos (GKOS) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Glaukos Corporation $GKOS Shares Sold by New York State Common Retirement Fund - MarketBeat
Glaukos (NYSE:GKOS) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
C WorldWide Group Holding A S Acquires 45,000 Shares of Glaukos Corporation $GKOS - MarketBeat
How FDA Approval of Repeat iDose TR Use Will Impact Glaukos (GKOS) Investors - simplywall.st
Glaukos Corporation $GKOS Shares Sold by Brown Capital Management LLC - MarketBeat
Liquidity Mapping Around (GKOS) Price Events - Stock Traders Daily
Director Sells GKOS 15,000 Shares for $1.9 Million - AOL.com
11,479 Shares in Glaukos Corporation $GKOS Bought by Y Intercept Hong Kong Ltd - MarketBeat
Assessing Glaukos (GKOS) Valuation After FDA Approval For Repeat iDose TR Use - simplywall.st
Glaukos Gains FDA Green Light For Repeat iDose TR Use - Yahoo Finance
Assessing Glaukos (GKOS) After Recent Share Price Rebound And DCF Upside Potential - Yahoo Finance
A Look At Glaukos (GKOS) Valuation After FDA Label Expansion For iDose TR - Yahoo Finance UK
How Investors May Respond To Glaukos (GKOS) FDA-Backed Repeat Protocol For iDose TR Implant - Yahoo Finance
Market Review: Will Glaukos Corporation outperform its industry peersJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Glaukos Achieves Regulatory and Commercial Milestones - AD HOC NEWS
Universal Beteiligungs und Servicegesellschaft mbH Sells 28,088 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos rises as FDA greenlights labeling update for iDose TR - MSN
Is Neonode Inc forming bullish engulfing patternsQuarterly Portfolio Summary & High Return Stock Watch Alerts - baoquankhu1.vn
Wells sees potential upside after Glaukos’ iDose repeat dosing label approved - Yahoo Finance
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Finviz
FDA approves Glaukos' iDose TR for repeat treatment labeling - Eyes On Eyecare
AustralianSuper Pty Ltd Increases Stock Position in Glaukos Corporation $GKOS - MarketBeat
Is Glaukos Corporation gaining market shareDip Buying & Free High Return Stock Watch Alerts - Mfd.ru
Glaukos Corporation (NYSE:GKOS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Glaukos Receives FDA Approval of NDA Supplement for Re-Administration of iDose TR - VisionMonday.com
FDA approves repeat treatment protocol for Glaukos’ iDose TR By Investing.com - Investing.com South Africa
Glaukos (NYSE:GKOS) Trading 6% Higher Following Analyst Upgrade - MarketBeat
Glaukos (NYSE:GKOS) Price Target Raised to $131.00 - MarketBeat
GKOS: BTIG Raises Price Target to $131 Amid Confidence in Glaukos | GKOS Stock News - GuruFocus
Glaukos stock rises on FDA approval for iDose TR re-administration - Investing.com
Glaukos stock rises on FDA approval for iDose TR re-administration By Investing.com - Investing.com South Africa
Glaukos (GKOS) Gains FDA Nod for iDose TR Re-administration Prot - GuruFocus
Glaukos (GKOS) Achieves FDA Approval for iDose Repeat Dosing Lab - GuruFocus
Glaukos wins FDA nod for iDose TR labeling update (GKOS:NYSE) - Seeking Alpha
Glaukos stock price target raised to $131 from $123 at BTIG on iDose approval By Investing.com - Investing.com Nigeria
Glaukos stock price target raised to $131 from $123 at BTIG on iDose approval - Investing.com Australia
FDA Approves Glaukos (GKOS) Repeat Administration Protocol for i - GuruFocus
Glaukos announces US FDA approval of NDA supplement allowing for re-administration of Idose® Tr - marketscreener.com
FDA approves repeat treatment protocol for Glaukos’ iDose TR - Investing.com
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR - Business Wire
Glaukos Corp (GKOS) Shares Gap Down to $120.3 on Jan 27 - GuruFocus
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):